{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"30"},{"groupId":"BG011","value":"27"},{"groupId":"BG012","value":"60"},{"groupId":"BG013","value":"65"},{"groupId":"BG014","value":"46"},{"groupId":"BG015","value":"47"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"32"},{"groupId":"BG018","value":"364"}],"units":"Participants"}],"groups":[{"description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG000","title":"10 mg QD (Phase 1)"},{"description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"BG001","title":"25 mg QD (Phase 1)"},{"description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG002","title":"50 mg QD (Phase 1)"},{"description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG003","title":"75 mg QD (Phase 1)"},{"description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG004","title":"100 mg QD (Phase 1)"},{"description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"BG005","title":"150 mg QD (Phase 1)"},{"description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG006","title":"200 mg QD (Phase 1)"},{"description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG007","title":"35 mg BID (Phase 1)"},{"description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG008","title":"75 mg BID (Phase 1)"},{"description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG009","title":"100 mg BID (Phase 1)"},{"description":"Treatment-naïve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG010","title":"EXP-1 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG011","title":"EXP-2 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG012","title":"EXP-3 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG013","title":"EXP-4 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG014","title":"EXP-5 (Phase 2)"},{"description":"Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"BG015","title":"EXP-6 (Phase 2)"},{"description":"Few Japanese participants were given PF-06463922 100 mg orally once daily (QD) in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal to evaluate safety of PF-06463922 in Japanese participants, in order to support inclusion of Japanese participants in Phase 2.","id":"BG016","title":"Japan Lead-In Cohort (LIC)"},{"description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.","id":"BG017","title":"Drug-drug Interaction (DDI) Sub-study"},{"description":"Total of all reporting groups","id":"BG018","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"}],"title":"<18 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"14"},{"groupId":"BG013","value":"19"},{"groupId":"BG014","value":"13"},{"groupId":"BG015","value":"12"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"5"},{"groupId":"BG018","value":"91"}],"title":"18-44 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"18"},{"groupId":"BG011","value":"13"},{"groupId":"BG012","value":"34"},{"groupId":"BG013","value":"37"},{"groupId":"BG014","value":"26"},{"groupId":"BG015","value":"27"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"20"},{"groupId":"BG018","value":"204"}],"title":"45-64 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"8"},{"groupId":"BG011","value":"9"},{"groupId":"BG012","value":"12"},{"groupId":"BG013","value":"9"},{"groupId":"BG014","value":"7"},{"groupId":"BG015","value":"8"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"7"},{"groupId":"BG018","value":"69"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"13"},{"groupId":"BG011","value":"17"},{"groupId":"BG012","value":"38"},{"groupId":"BG013","value":"37"},{"groupId":"BG014","value":"25"},{"groupId":"BG015","value":"27"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"15"},{"groupId":"BG018","value":"206"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"17"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"22"},{"groupId":"BG013","value":"28"},{"groupId":"BG014","value":"21"},{"groupId":"BG015","value":"20"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"17"},{"groupId":"BG018","value":"158"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"10"},{"groupId":"BG011","value":"13"},{"groupId":"BG012","value":"25"},{"groupId":"BG013","value":"32"},{"groupId":"BG014","value":"27"},{"groupId":"BG015","value":"25"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"21"},{"groupId":"BG018","value":"190"}],"title":"WHITE"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"6"}],"title":"BLACK"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"17"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"23"},{"groupId":"BG013","value":"23"},{"groupId":"BG014","value":"14"},{"groupId":"BG015","value":"16"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"11"},{"groupId":"BG018","value":"124"}],"title":"ASIAN"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"2"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"13"}],"title":"Others"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"10"},{"groupId":"BG013","value":"7"},{"groupId":"BG014","value":"3"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"31"}],"title":"Unspecified"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The safety analysis set included all enrolled patients who receive at least one dose of PF-06463922 (including Lead-in dose)."}